Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUNCtion ALS
2025-523111-11-00Phase 2Authorised
- Sponsor
- Trace Neuroscience
- Start
- Jun 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing TRCN-1023 single ascending dose with Placebo (2 arms). Primary endpoint: Frequency of adverse events. Planned start Jun 2026; status: authorised.
02
Drugs
TRCN-1023
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2025-523111-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523111-11-00.